Angioedema is a skin disease characterized by episodic swellings of the deeper layers of the skin and other tissues such as the gut, throat, and airway. It can be caused due to genetic disorders, drugs, foods, bites, or stings. Angioedema is a painful, potentially life-threatening condition if not treated properly and on time. The increasing prevalence of angioedema globally is primarily driving the growth of the angioedema treatment market.
The global angioedema treatment market is estimated to be valued at US$ 470.4 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030.
Key Takeaways
Key players: Key players operating in the angioedema treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. Bayer AG dominates the global market with its product berinert which is leading injectable treatment for hereditary angioedema.
Growing demand: The growing hereditary angioedema patient pool coupled with rising awareness about early diagnosis and treatment is fueling the demand for novel drugs and devices for angioedema treatment. According to studies, around 1 in 10,000 to 1 in 50,000 people globally have hereditary angioedema.
Market Trends
Shift towards home-based care: With advancement in self-administration medical devices and home infusion therapies, there is a shift towards home-based care for angioedema treatment. This trend allows patients to avoid hospital visits and emergency department admissions.
Market Opportunities
Emerging markets: emerging countries in Asia Pacific and Latin America with large patient population present lucrative opportunities for angioedema drug manufacturers given low treatment rates in these regions currently.
In terms of geographical regions, North America is a concentrated market for angioedema treatment in terms of value. The region accounted for around 40% of the global market value in 2023 on account of developed healthcare infrastructure, availability of advanced treatment options and appropriate reimbursement policies. Growing patient awareness about available treatment options is also boosting the North American market.
Asia Pacific region is poised to witness the fastest growth for angioedema treatment market during the forecast period. Factors like rising healthcare expenditures, increasing diagnosis and treatment rates, growing research collaborations and rising healthcare standards are expected to drive strong market growth in Asia Pacific. China and India offer immense untapped market potential and are emerging hotspots for investments in this space.
